<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidemiological studies suggest that colonic production of <z:chebi fb="0" ids="17968">butyrate</z:chebi> and <z:chebi fb="0" ids="50114">estrogen</z:chebi> may be involved in human susceptibility to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="17263">Estrone</z:chebi> (E1) can be produced by the aromatase pathway during the conversion of androstenedione (A) to E1 </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we studied the effect of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (NaBu) on the CYP19A1 transcript and protein levels and on the conversion of A to E1 in HT29, DLD-1 and LoVo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>We found that NaBu significantly downregulated CYP19A1 transcript and protein levels, a phenomenon that was associated with reduced conversion of A to E1 in HT29, DLD-1 and LoVo cells </plain></SENT>
<SENT sid="4" pm="."><plain>Our studies demonstrated that, although <z:chebi fb="0" ids="17968">butyrate</z:chebi> exhibited a protective role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development, this compound may reduce aromatase activity and the production of E1 in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
</text></document>